Plasmodium vivax is the most common species of human malaria parasite found outside Africa, with high endemicity in Asia, Central and South America, and Oceania. Although Plasmodium falciparum causes the majority of deaths, P. vivax can lead to severe malaria and result in significant morbidity and mortality. The development of a protective vaccine will be a major step toward malaria elimination. Recently, a formulation containing the three allelic variants of the P. vivax circumsporozoite protein (PvCSP—All epitopes) showed partial protection in mice after a challenge with the hybrid Plasmodium berghei (Pb) sporozoite, in which the PbCSP central repeats were replaced by the VK210 PvCSP repeats (Pb/Pv sporozoite). In the present study, the chimeric PvCSP allelic variants (VK210, VK247, and P. vivax-like) were fused with the mumps virus nucleocapsid protein in the absence (NLP-CSPR) or presence of the conserved C-terminal (CT) domain of PvCSP (NLP-CSPCT). To elicit stronger humoral and cellular responses, Pichia pastoris yeast was used to assemble them as nucleocapsid-like particles (NLPs). Mice were immunized with each recombinant protein adjuvanted with Poly (I:C) and presented a high frequency of antigen-specific antibody-secreting cells (ASCs) on days 5 and 30, respectively, in the spleen and bone marrow. Moreover, high IgG titers against all PvCSP variants were detected in the sera. Later, these immunized mice with NLP-CSPCT were challenged with Pb/Pv sporozoites. Sterile protection was observed in 30% of the challenged mice. Therefore, this vaccine formulation use has the potential to be a good candidate for the development of a universal vaccine against P. vivax malaria.
Malaria remains a world health challenge; in 2023, 263 million cases and 597,000 deaths were reported around the globe. The parasite's life cycle is complex, and targeted interventions at critical developmental stages are needed to effectively control the disease. Transmission-blocking (TB) strategies aim to interrupt Plasmodium transmission by targeting either the mosquito vector or the parasite's sexual stages through vaccines and drugs. TB interventions can focus on gametocytes in the human host or other forms in the mosquito midgut, such as gametes, zygotes, ookinetes, and oocysts. The development of new TB approaches faces significant challenges. Studying the parasite's sexual stages is inherently difficult, and high-throughput screening (HTS) for gametocytocidal compounds relies primarily on P. falciparum cultures. However, robust in vitro tools for assessing interventions against later sexual stages remain limited. To accelerate the discovery of TB compounds, our group developed a novel HTS assay for gametocyte activation and fertilization using P. berghei, a murine model of Plasmodium infection. The transgenic parasite, Ookluc, expresses nanoluciferase exclusively after zygote formation, with peak luminescence during ookinete development. This luminescence-based assay provides a quantitative readout of gamete to zygote and zygote to ookinete differentiation, where increased luminescence directly correlates with ookinete formation. This video article presents the methods for screening malaria TB compounds using Ookluc.
Malaria remains a world health challenge; in 2023, 263 million cases and 597,000 deaths were reported around the globe. The parasite's life cycle is complex, and targeted interventions at critical developmental stages are needed to effectively control the disease. Transmission-blocking (TB) strategies aim to interrupt Plasmodium transmission by targeting either the mosquito vector or the parasite's sexual stages through vaccines and drugs. TB interventions can focus on gametocytes in the human host or other forms in the mosquito midgut, such as gametes, zygotes, ookinetes, and oocysts. The development of new TB approaches faces significant challenges. Studying the parasite's sexual stages is inherently difficult, and high-throughput screening (HTS) for gametocytocidal compounds relies primarily on P. falciparum cultures. However, robust in vitro tools for assessing interventions against later sexual stages remain limited. To accelerate the discovery of TB compounds, our group developed a novel HTS assay for gametocyte activation and fertilization using P. berghei, a murine model of Plasmodium infection. The transgenic parasite, Ookluc, expresses nanoluciferase exclusively after zygote formation, with peak luminescence during ookinete development. This luminescence-based assay provides a quantitative readout of gamete to zygote and zygote to ookinete differentiation, where increased luminescence directly correlates with ookinete formation. This video article presents the methods for screening malaria TB compounds using Ookluc.